# US 2021/0330760 A1 · Methods and materials for treating osteoarthritis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330760 A1 - Document ID: US20210330760A1 - Status: Published application - Kind: A1 - Application number: 17/236,726 - Filed: 2021-04-21 - Published: 2021-10-28 - Earliest claimed: 2020-04-22 - Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education - Inventors: Fabrisia Ambrosio; Hirotaka Iijima - Web page: https://patentgrep.com/patent/US20210330760A1 ## CPC - A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered} - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)} - C12N 15/86: Viral vectors - C12Y 302/01031: Beta-glucuronidase (3.2.1.31) - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - C12N 2750/14043: viral genome or elements thereof as genetic vector - C12N 2750/14143: viral genome or elements thereof as genetic vector - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Y: ENZYMES ## Abstract This document provides methods and materials for treating osteoarthritis. For example, a mammal having, or at risk for developing, osteoarthritis can be treated by increasing the level of one or more Klotho polypeptides (e.g., one or more alpha-Klotho (α-Klotho) polypeptides) within cells (e.g., chondrocytes) within the mammal. ## Claims ### Claim 1 A method for treating a mammal having osteoarthritis, wherein said method comprises administering an α-Klotho polypeptide or nucleic acid encoding said α-Klotho polypeptide to a mammal identified as having osteoarthritis. ### Claim 2 (depends on 1) The method of claim 1, wherein said mammal is a human. ### Claim 3 (depends on 1) The method of claim 1, wherein said method comprises administering said α-Klotho polypeptide to said mammal. ### Claim 4 (depends on 1) The method of claim 1, wherein said method comprises administering said nucleic acid to said mammal. ### Claim 5 (depends on 4) The method of claim 4, wherein said nucleic acid is a viral vector. ### Claim 6 (depends on 4) The method of claim 4, wherein said nucleic acid is naked DNA. ### Claim 7 (depends on 1) The method of claim 1, wherein said osteoarthritis is present in a knee of said mammal. ### Claim 8 (depends on 1) The method of claim 1, wherein said administering comprises an intra-articular injection. ### Claim 9 (depends on 1) The method of claim 1, wherein said administering comprises an intravenous injection. ### Claim 10 A method for improving cartilage integrity within a mammal having osteoarthritis, wherein said method comprises administering an α-Klotho polypeptide or nucleic acid encoding said α-Klotho polypeptide to a mammal identified as having osteoarthritis. ### Claim 11 (depends on 10) The method of claim 10, wherein said mammal is a human. ### Claim 12 (depends on 10) The method of claim 10, wherein said method comprises administering said α-Klotho polypeptide to said mammal. ### Claim 13 (depends on 10) The method of claim 10, wherein said method comprises administering said nucleic acid to said mammal. ### Claim 14 (depends on 13) The method of claim 13, wherein said nucleic acid is a viral vector. ### Claim 15 (depends on 13) The method of claim 13, wherein said nucleic acid is naked DNA. ### Claim 16 (depends on 10) The method of claim 10, wherein said osteoarthritis is present in a knee of said mammal. ### Claim 17 (depends on 10) The method of claim 10, wherein said administering comprises an intra-articular injection. ### Claim 18 (depends on 10) The method of claim 10, wherein said administering comprises an intravenous injection. ### Claim 19 A method for reducing cartilage degeneration within a mammal having osteoarthritis, wherein said method comprises administering an α-Klotho polypeptide or nucleic acid encoding said α-Klotho polypeptide to a mammal identified as having osteoarthritis. ### Claim 20 (depends on 19) The method of claim 19, wherein said mammal is a human. ### Claim 21 (depends on 19) The method of claim 19, wherein said method comprises administering said α-Klotho polypeptide to said mammal. ### Claim 22 (depends on 19) The method of claim 19, wherein said method comprises administering said nucleic acid to said mammal. ### Claim 23 (depends on 22) The method of claim 22, wherein said nucleic acid is a viral vector. ### Claim 24 (depends on 22) The method of claim 22, wherein said nucleic acid is naked DNA. ### Claim 25 (depends on 19) The method of claim 19, wherein said osteoarthritis is present in a knee of said mammal. ### Claim 26 (depends on 19) The method of claim 19, wherein said administering comprises an intra-articular injection. ### Claim 27 (depends on 19) The method of claim 19, wherein said administering comprises an intravenous injection.